ClinicalTrials.gg
CompletedNCT05905796eRADARUpdated Oct 6, 2026Results posted

The Brain Health Study: A Pragmatic, Patient-Centered Trial

An interventional study of Brain Health Assessment in Dementia and Alzheimer Disease, sponsored by University of California, San Francisco. Completed at 3 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2022, registered Jun 2023).
Updated Oct 6, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,261
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Alzheimer Disease by University of California, San Francisco — 3 open to participants now, 5 under way, none of them phase 3. Alzheimer Disease · University of California, San Francisco.

Enrollment
2nd of 15
1,261 · median 66
Started
2022
the only one that year
No phase
13 of 17
2 open now
Registered
14th of 17
by date

Among the 17 studies in Alzheimer Disease by University of California, San Francisco, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 13 with no phase, and was the 14th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 17 studies in Alzheimer Disease by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by University of California, San Francisco, or all of them as a file.
02

Study summary

The eRADAR Brain Health Study is an embedded, pragmatic clinical trial to determine whether targeted screening for dementia using the eRADAR algorithm increases dementia detection within primary care compared to usual care.

Read the detailed description

eRADAR stands for "electronic health record (EHR) Risk of Alzheimer's and Dementia Assessment Rule." It is a low-cost tool or algorithm that uses readily available EHR data elements to identify patients at risk of undiagnosed dementia. The investigators will conduct a pragmatic randomized controlled trial to assess the impact of implementing eRADAR as part of a supported outreach process on dementia detection rates. The investigators will also explore the impact of eRADAR implementation on healthcare utilization and patient experience.

03

Conditions studied

  • Dementia
  • Alzheimer Disease

Browse trials for

04

In context

Alzheimer Disease Reclassified

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's enrollment of 1,261 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.

Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No prior diagnosis of dementia (defined from EHR diagnosis codes) and not receiving medications for dementia
  • Active patient at participating clinic
  • Adequate data to calculate eRADAR score

Exclusion criteria

Exclusion Criteria:

- Currently receiving hospice care

06

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,261 participants (actual)

Study arms

  • Experimental
    Brain Health Intervention

    Participants in the intervention arm were invited to attend a "brain health" visit with a trained research interventionist who was a licensed clinician (e.g., social worker.) They were sent a mailed outreach letter and information sheet, with follow-up phone calls. At the visit, the research interventionist asked about memory symptoms and ability to perform instrumental activities of daily living (IADLs) and screened for cognitive impairment and depression. Results were shared with the participant and their primary care physician (PCP), who was responsible for follow up and more evaluation if needed and for making a final diagnosis of dementia, if applicable.

    Other: Brain Health Assessment

  • No intervention
    Usual Care

    Individuals in this arm did not receive any intervention but rather usual care. University of California, San Francisco (UCSF) does not routinely screen for cognitive impairment (in line with current guidelines from the US Preventive Services Task Force).

Interventions

  • OtherBrain Health Assessment

    Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.

07

What researchers measure

Primary outcomes

  1. New Diagnoses of Dementia (12 Months)

    Number of patients who received new dementia diagnoses within 12 months, identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes

    Time frame: 12 months after index date

Secondary outcomes

  1. New Diagnoses of Dementia or Mild Cognitive Impairment (12 Months)

    Number of patients who received a new diagnosis of dementia or mild cognitive impairment within 12 months, defined from EHR data

    Time frame: 12 months after index date

  2. New Diagnoses of Dementia (18 Months)

    Number of patients who received a new diagnosis of dementia within 18 months of index date, defined from EHR data

    Time frame: 18 months after index date

  3. New Diagnoses of Dementia (6 Months)

    Number of patients receiving new dementia diagnoses within 6 months of index date, defined using EHR data

    Time frame: 6 months after index date

  4. New Dementia Medications (12 Months)

    Number of patients who received a new medication for dementia in 12 months, defined from medication orders or dispensings in the electronic health record

    Time frame: 12 months after index date

  5. Urgent Care or Emergency Department Visits (12 Months)

    Number of patients who had at least 1 urgent care or emergency department visit in the 12 months following their index date

    Time frame: 12 months after index date

  6. Hospitalizations and Inpatient Admissions (12 Months)

    Average number of hospitalizations and inpatient stays per participant within 12 months of index date

    Time frame: 12 months after index date

  7. Scheduled Visits Missed (12 Months)

    Average number of scheduled clinic visits missed ("no shows") per participant

    Time frame: 12 months after index date

  8. Primary Care Visits (6 Months)

    Average number of visits per participant in primary care within 6 months after the index date

    Time frame: 6 months after index date

  9. Primary Care Visits (12 Months)

    Average number of primary care visits per participant in the 12 months after their index date

    Time frame: 12 months after index date

  10. B-12 Lab Tests (12 Months)

    Number of patients with at least one B12 lab test in the 12 months after their index date

    Time frame: 12 months after index date

  11. Neuroimaging Tests (12 Months)

    Number of patients with at least one neuroimaging study (CT head, MRI brain) in the 12 months after their index date

    Time frame: 12 months after index date

  12. Neurology Referrals (12 Months)

    Number of patients with at least one referral to Neurology or the Memory and Aging Center in the 12 months after their index date

    Time frame: 12 months after index date

08

Results

Posted Oct 6, 2026

Participant flow

A research study programmer extracted EHR data to identify patients who met eligibility criteria within each study clinic. Eligible patients were then randomized in blocks based on their primary care provider to intervention or usual care groups. The date of randomization was used as their initiation date into the study. All patients initiated were followed through the electronic health record for outcomes, except those who were later found to have died prior to the initiation date.

Participant flow — Overall Study
MilestoneBrain Health InterventionUsual Care
Started683578
Completed681575
Not completed23
Withdrew: Found to have died prior to initiation into study23

Outcome measures

PrimaryNew Diagnoses of Dementia (12 Months)

Number of patients who received new dementia diagnoses within 12 months, identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
New Diagnoses of Dementia (12 Months)
ParticipantsBrain Health InterventionUsual Care
New Diagnoses of Dementia (12 Months)2621
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equations · p = 0.87 · Risk ratio (rr): 1.05 · 95% CI 0.59 to 1.86Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryNew Diagnoses of Dementia or Mild Cognitive Impairment (12 Months)

Number of patients who received a new diagnosis of dementia or mild cognitive impairment within 12 months, defined from EHR data

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
New Diagnoses of Dementia or Mild Cognitive Impairment (12 Months)
ParticipantsBrain Health InterventionUsual Care
New Diagnoses of Dementia or Mild Cognitive Impairment (12 Months)6937
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equations · p = 0.013 · Risk ratio (rr): 1.60 · 95% CI 1.10 to 2.33Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryNew Diagnoses of Dementia (18 Months)

Number of patients who received a new diagnosis of dementia within 18 months of index date, defined from EHR data

Time frame:
18 months after index date
Reported as:
Count of participants · Participants
New Diagnoses of Dementia (18 Months)
ParticipantsBrain Health InterventionUsual Care
New Diagnoses of Dementia (18 Months)3230
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.69 · Risk ratio (rr): 0.90 · 95% CI 0.55 to 1.49Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryNew Diagnoses of Dementia (6 Months)

Number of patients receiving new dementia diagnoses within 6 months of index date, defined using EHR data

Time frame:
6 months after index date
Reported as:
Count of participants · Participants
New Diagnoses of Dementia (6 Months)
ParticipantsBrain Health InterventionUsual Care
New Diagnoses of Dementia (6 Months)1010
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.75 · Risk ratio (rr): 0.87 · 95% CI 0.36 to 2.08Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryNew Dementia Medications (12 Months)

Number of patients who received a new medication for dementia in 12 months, defined from medication orders or dispensings in the electronic health record

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
New Dementia Medications (12 Months)
ParticipantsBrain Health InterventionUsual Care
New Dementia Medications (12 Months)78
SecondaryUrgent Care or Emergency Department Visits (12 Months)

Number of patients who had at least 1 urgent care or emergency department visit in the 12 months following their index date

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
Urgent Care or Emergency Department Visits (12 Months)
ParticipantsBrain Health InterventionUsual Care
Urgent Care or Emergency Department Visits (12 Months)217180
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.89 · Risk ratio (rr): 0.99 · 95% CI 0.84 to 1.16Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryHospitalizations and Inpatient Admissions (12 Months)

Average number of hospitalizations and inpatient stays per participant within 12 months of index date

Time frame:
12 months after index date
Reported as:
Mean · inpatient stays
Hospitalizations and Inpatient Admissions (12 Months)
inpatient staysBrain Health InterventionUsual Care
Hospitalizations and Inpatient Admissions (12 Months)0.35 ± 0.920.28 ± 0.69
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.16 · Risk ratio (rr): 1.23 · 95% CI 0.92 to 1.64Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryScheduled Visits Missed (12 Months)

Average number of scheduled clinic visits missed ("no shows") per participant

Time frame:
12 months after index date
Reported as:
Mean · missed visits
Scheduled Visits Missed (12 Months)
missed visitsBrain Health InterventionUsual Care
Scheduled Visits Missed (12 Months)0.13 ± 0.510.16 ± 0.49
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.56 · Risk ratio (rr): 0.90 · 95% CI 0.62 to 1.30Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryPrimary Care Visits (6 Months)

Average number of visits per participant in primary care within 6 months after the index date

Time frame:
6 months after index date
Reported as:
Mean · visits
Primary Care Visits (6 Months)
visitsBrain Health InterventionUsual Care
Primary Care Visits (6 Months)1.68 ± 1.621.87 ± 1.82
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.06 · Risk ratio (rr): 0.90 · 95% CI 0.81 to 1.00Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryPrimary Care Visits (12 Months)

Average number of primary care visits per participant in the 12 months after their index date

Time frame:
12 months after index date
Reported as:
Mean · visits
Primary Care Visits (12 Months)
visitsBrain Health InterventionUsual Care
Primary Care Visits (12 Months)3.26 ± 2.693.57 ± 2.99
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.09 · Risk ratio (rr): 0.92 · 95% CI 0.84 to 1.01Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryB-12 Lab Tests (12 Months)

Number of patients with at least one B12 lab test in the 12 months after their index date

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
B-12 Lab Tests (12 Months)
ParticipantsBrain Health InterventionUsual Care
B-12 Lab Tests (12 Months)189177
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.22 · Risk ratio (rr): 0.90 · 95% CI 0.76 to 1.07Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryNeuroimaging Tests (12 Months)

Number of patients with at least one neuroimaging study (CT head, MRI brain) in the 12 months after their index date

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
Neuroimaging Tests (12 Months)
ParticipantsBrain Health InterventionUsual Care
Neuroimaging Tests (12 Months)10689
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.87 · Risk ratio (rr): 0.98 · 95% CI 0.75 to 1.27Generalized estimating equations with log-link and cluster-robust standard errors
SecondaryNeurology Referrals (12 Months)

Number of patients with at least one referral to Neurology or the Memory and Aging Center in the 12 months after their index date

Time frame:
12 months after index date
Reported as:
Count of participants · Participants
Neurology Referrals (12 Months)
ParticipantsBrain Health InterventionUsual Care
Neurology Referrals (12 Months)5937
Statistical analysis
  • Brain Health Intervention vs Usual Care · Generalized estimating equation · p = 0.12 · Risk ratio (rr): 1.37 · 95% CI 0.92 to 2.05Generalized estimating equations with log-link and cluster-robust standard errors

Adverse events

Collected over From participant index date to end of follow-up, up to 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brain Health Intervention53/681 (7.8%)239/681 (35.1%)78/681 (11.5%)
Usual Care33/575 (5.7%)162/575 (28.2%)52/575 (9%)
Most frequent serious events
Most frequent serious events
EventBrain Health InterventionUsual Care
HospitalizationsGeneral disorders239/681162/575
Most frequent other events
Most frequent other events
EventBrain Health InterventionUsual Care
New depression diagnosisPsychiatric disorders50/50036/413
New start of antidepressantPsychiatric disorders37/42925/345
Suicidal ideationPsychiatric disorders3/6810/575
Suicide attemptPsychiatric disorders0/6810/575

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brain Health InterventionUsual CareTotal
Mean84.66 ± 5.7784.82 ± 5.6784.73 ± 5.73
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Brain Health InterventionUsual CareTotal
Female361346707
Male319229548
Non-binary101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brain Health InterventionUsual CareTotal
Asian234171405
Black or African American5862120
Hispanic or Latino (any race)5856114
White299250549
Another or More Than One Race283058
Unknown or not reported4610
Elixhauser comorbidity score
Elixhauser comorbidity score(score on a scale)Brain Health InterventionUsual CareTotal
Mean7.23 ± 8.517.15 ± 8.047.19 ± 8.29
eRADAR score
eRADAR score(Score on a scale)Brain Health InterventionUsual CareTotal
Mean0.06 ± 0.040.06 ± 0.040.06 ± 0.04
Prior diagnosis of mild cognitive impairment
Prior diagnosis of mild cognitive impairment(Participants)Brain Health InterventionUsual CareTotal
Count of participants202646
Prior diagnosis of memory problem or concern
Prior diagnosis of memory problem or concern(Participants)Brain Health InterventionUsual CareTotal
Count of participants7562137
09

Study locations

3 sites
  • UCSF Primary Care at China Basin
    San Francisco, California 94107, United States
  • Division of General Internal Medicine
    San Francisco, California 94115, United States
  • Women's Health Primary Care
    San Francisco, California 94143, United States
10

References and documents

Publications

  • Dublin S, Greenwood-Hickman MA, Karliner L, Hsu C, Coley RY, Colemon L, Carrasco A, King D, Grace A, Lee SJ, Walsh JME, Barrett T, Broussard J, Singh U, Idu A, Yaffe K, Boustani M, Barnes DE. The electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) Brain Health Trial: Protocol for an embedded, pragmatic clinical trial of a low-cost dementia detection algorithm. Contemp Clin Trials. 2023 Dec;135:107356. doi: 10.1016/j.cct.2023.107356. Epub 2023 Oct 17. PubMed 37858616 ↗
  • Lee SJ, Larson EB, Dublin S, Walker R, Marcum Z, Barnes D. A Cohort Study of Healthcare Utilization in Older Adults with Undiagnosed Dementia. J Gen Intern Med. 2018 Jan;33(1):13-15. doi: 10.1007/s11606-017-4162-3. No abstract available. PubMed 28849435 ↗
  • Barnes DE, Zhou J, Walker RL, Larson EB, Lee SJ, Boscardin WJ, Marcum ZA, Dublin S. Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia. J Am Geriatr Soc. 2020 Jan;68(1):103-111. doi: 10.1111/jgs.16182. Epub 2019 Oct 14. PubMed 31612463 ↗
  • Coley RY, Smith JJ, Karliner L, Idu AE, Lee SJ, Fuller S, Lam R, Barnes DE, Dublin S. External Validation of the eRADAR Risk Score for Detecting Undiagnosed Dementia in Two Real-World Healthcare Systems. J Gen Intern Med. 2023 Feb;38(2):351-360. doi: 10.1007/s11606-022-07736-6. Epub 2022 Jul 29. PubMed 35906516 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — This Individual Participant Data (IPD) plan applies to all quantitative study data, such as data collected specifically for the study and those derived from electronic health records (EHR), as well as the data collected via planned study surveys, which include only short qualitative free-text fields. The investigators do not plan to share transcripts from in-depth qualitative interviews or recorded study assessment visits. Data will be maintained on secure servers behind the firewalls at the University of California, San Francisco (UCSF). De-identified or limited datasets containing individual-level data on which publications are based will be made available to qualified researchers for specified analyses. The investigators will make the data available to users only under a data-use agreement (DUA).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be requested after the primary study paper is accepted for publication, up until 5 years after study completion.

Access criteria: Individuals interested in using data will be required to complete a standard form, sign a Data Use Agreement (DUA) and provide documentation of IRB approval. User registration will be required in order to access or download data files. As part of the registration process, users must agree to the conditions of use governing access to the data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgment of the data resource. The UCSF Industry Contracts Division (ICD), which oversees incoming and outgoing transfer of all UCSF data, will review registration materials for compliance with UCSF policies.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2025, 33 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 33 months is close to that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 15, 2023
StartActual
Dec 7, 2022
Primary completionActual
Oct 6, 2025
CompletionActual
Jan 26, 2026
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Enrollment
1271→1261
Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore New dementia diagnosisNow New Diagnoses of Dementia (12 Months)Time frame: 12 months after index date
Oct 6, 2026
Documents
Secondary outcomes
6 edited, 6 added, 8 removed
What changed in the outcomes
  • EditedNumber of primary care visitsPrimary Care Visits (6 Months)Time frame: 6 months after index date
  • EditedNumber of urgent care and emergency department visitsUrgent Care or Emergency Department Visits (12 Months)Time frame: 1 year after index date → 12 months after index date
  • EditedNumber of scheduled visits missedScheduled Visits Missed (12 Months)Time frame: 1 year after index date → 12 months after index date
  • EditedNew dementia diagnosisDiagnoses of Dementia (secondary definitions18 Months)Time frame: 6 months after index date → 18 months after index date
  • EditedNew dementia diagnosisDiagnoses of Dementia (secondary definitions6 Months)Time frame: 18 months after index date → 6 months after index date
  • EditedNew diagnosisDiagnoses of mild cognitive impairmentDementia or Mild Cognitive Impairment (12 Months)Time frame: 12 months after index date
  • AddedNew Dementia Medications (12 Months)Time frame: 12 months after index date
  • AddedHospitalizations and Inpatient Admissions (12 Months)Time frame: 12 months after index date
  • AddedPrimary Care Visits (12 Months)Time frame: 12 months after index date
  • AddedB-12 Lab Tests (12 Months)Time frame: 12 months after index date
  • AddedNeuroimaging Tests (12 Months)Time frame: 12 months after index date
  • AddedNeurology Referrals (12 Months)Time frame: 12 months after index date
  • RemovedNumber of dementia-related laboratory tests performedTime frame: 6 months after index date
  • RemovedNumber of dementia-related neuroimaging tests performedTime frame: 6 months after index date
  • RemovedNumber of specialty visits or referrals for dementia assessmentTime frame: 6 months after index date
  • RemovedPercent of participants who receive new medications for dementiaTime frame: 6 months after index date
  • RemovedNumber of inpatient daysTime frame: 1 year after index date
  • RemovedProportion of days covered for current prescriptionsTime frame: 1 year after index date
  • RemovedProportion of people offered a brain health visit who accept and attend the visitTime frame: 3 months after invitation mailed
  • RemovedPositive predictive value of eRADAR algorithmTime frame: 12 months after index date
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Enrollment 1271→1261
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore New dementia diagnosisNow New Diagnoses of Dementia (12 Months)Time frame: 12 months after index date
    Secondary outcomes 6 edited, 6 added, 8 removed
    What changed in the outcomes
    • EditedNumber of primary care visitsPrimary Care Visits (6 Months)Time frame: 6 months after index date
    • EditedNumber of urgent care and emergency department visitsUrgent Care or Emergency Department Visits (12 Months)Time frame: 1 year after index date → 12 months after index date
    • EditedNumber of scheduled visits missedScheduled Visits Missed (12 Months)Time frame: 1 year after index date → 12 months after index date
    • EditedNew dementia diagnosisDiagnoses of Dementia (secondary definitions18 Months)Time frame: 6 months after index date → 18 months after index date
    • EditedNew dementia diagnosisDiagnoses of Dementia (secondary definitions6 Months)Time frame: 18 months after index date → 6 months after index date
    • EditedNew diagnosisDiagnoses of mild cognitive impairmentDementia or Mild Cognitive Impairment (12 Months)Time frame: 12 months after index date
    • AddedNew Dementia Medications (12 Months)Time frame: 12 months after index date
    • AddedHospitalizations and Inpatient Admissions (12 Months)Time frame: 12 months after index date
    • AddedPrimary Care Visits (12 Months)Time frame: 12 months after index date
    • AddedB-12 Lab Tests (12 Months)Time frame: 12 months after index date
    • AddedNeuroimaging Tests (12 Months)Time frame: 12 months after index date
    • AddedNeurology Referrals (12 Months)Time frame: 12 months after index date
    • RemovedNumber of dementia-related laboratory tests performedTime frame: 6 months after index date
    • RemovedNumber of dementia-related neuroimaging tests performedTime frame: 6 months after index date
    • RemovedNumber of specialty visits or referrals for dementia assessmentTime frame: 6 months after index date
    • RemovedPercent of participants who receive new medications for dementiaTime frame: 6 months after index date
    • RemovedNumber of inpatient daysTime frame: 1 year after index date
    • RemovedProportion of days covered for current prescriptionsTime frame: 1 year after index date
    • RemovedProportion of people offered a brain health visit who accept and attend the visitTime frame: 3 months after invitation mailed
    • RemovedPositive predictive value of eRADAR algorithmTime frame: 12 months after index date
    + 7 other changes: verification date, description, design details, arm descriptions, data sharing statement, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05905796
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Dec 7, 2022
Primary completion
Oct 6, 2025
Completion
Jan 26, 2026
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Deborah Barnes, PhD
principal investigator · University of California, San Francisco
Sascha Dublin, MD, PhD
principal investigator · KP Washington Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion